User profiles for R. E. Coleman

Robert Coleman

University of Sheffield
Verified email at sheffield.ac.uk
Cited by 75529

Clinical features of metastatic bone disease and risk of skeletal morbidity

RE Coleman - Clinical cancer research, 2006 - AACR
Coleman: In this data set, we don't have CA15-3, so we're limited to an analysis in prostate
cancer, where obviously PSA was measured regularly. There is literature comparing bone …

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

RE Coleman - Cancer treatment reviews, 2001 - Elsevier
Metastatic bone disease develops as a result of the many interactions between tumour cells
and bone cells. This leads to disruption of normal bone metabolism, with the increased …

Skeletal complications of malignancy

RE Coleman - … International Journal of the American Cancer …, 1997 - Wiley Online Library
The skeleton is the most common organ to be affected by metastatic cancer, and tumors
arising from the breast, prostate, thyroid, lung, and kidney possess a special propensity to …

The clinical course of bone metastases from breast cancer

RE Coleman, RD Rubens - British journal of cancer, 1987 - nature.com
RE Coleman & RD Rubens … Preliminary results show that prediction of objective response
within 3-4 weeks of starting treatment is possible (Coleman et al., unpublished data). Morbidity …

A tabulated summary of the FDG PET literature

…, DHS Silverman, RE Coleman… - Journal of nuclear …, 2001 - Soc Nuclear Med
… Appendix A gives details on the way in which literature was searched and analyzed, and
Appendix B reports some alternate approaches to summarizing the data. The average FDG …

Recommendations on the use of 18F-FDG PET in oncology

…, VJ Lowe, GH Lyman, RE Coleman… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The rationale was to develop recommendations on the use of 18 F-FDG PET in breast,
colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, …

[BOOK][B] The master plan of evangelism

RE Coleman - 2006 - books.google.com
… world evangelization in our generation as Robert Coleman’s The Master Plan of Evangelism…
Coleman has gone back to the Bible and has asked one critical question: What was Christ’s …

Use of florbetapir-PET for imaging β-amyloid pathology

…, ML Flitter, MJ Krautkramer, HF Kung, RE Coleman… - Jama, 2011 - jamanetwork.com
… Dr Coleman reported being on the medical advisory board for General Electric
Healthcare from 2003-2008; being a consultant for General Electric Healthcare from 2003-2008; …

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

…, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman… - The Lancet, 2007 - thelancet.com
Background Early improvements in disease-free survival have been noted when an aromatase
inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal …

Clinical applications of PET in oncology

EM Rohren, TG Turkington, RE Coleman - Radiology, 2004 - pubs.rsna.org
Positron emission tomography (PET) provides metabolic information that has been documented
to be useful in patient care. The properties of positron decay permit accurate imaging of …